Literature DB >> 27600136

Utilizing In Vitro Dissolution-Permeation Chamber for the Quantitative Prediction of pH-Dependent Drug-Drug Interactions with Acid-Reducing Agents: a Comparison with Physiologically Based Pharmacokinetic Modeling.

Andy Z X Zhu1, Ming-Chih David Ho2, Christopher K Gemski2, Bei-Ching Chuang2, Mingxiang Liao2, Cindy Q Xia2.   

Abstract

For many orally administered basic drugs with pH-dependent solubility, concurrent administration with acid-reducing agents (ARAs) can significantly impair their absorption and exposure. In this study, pH-dependent drug-drug interaction (DDI) prediction methods, including in vitro dissolution-permeation chamber (IVDP) and physiologically based pharmacokinetic (PBPK) modeling, were evaluated for their ability to quantitatively predict the clinical DDI observations using 11 drugs with known clinical pH-dependent DDI data. The data generated by IVDP, which consists of a gastrointestinal compartment and a systemic compartment separated by a biomimic membrane, significantly correlated with the clinical DDI observations. The gastrointestinal compartment AUC ratio showed strong correlation with clinical AUC ratio (R=0.72 and P=0.0056), and systemic compartment AUC ratio showed strong correlation with clinical Cmax ratio (R=0.91 and P=0.0003). PBPK models were also developed for the 11 test compounds. The simulations showed that the predictions from PBPK model with experimentally measured parameters significantly correlated with the clinical DDI observations. Future studies are needed to evaluate predictability of Z-factor-based PBPK models for pH-dependent DDI. Overall, these data suggested that the severity of pH-dependent DDI can be predicted by in vitro and in silico methods. Proper utilization of these methods before clinical DDI studies could allow adequate anticipation of pH-dependent DDI, which helps with minimizing pharmacokinetic variation in clinical studies and ensuring every patient with life-threatening diseases receives full benefit of the therapy.

Entities:  

Keywords:  acid-reducing agents; drug absorption; drug-drug interaction; pH effect; proton-pump inhibitors

Mesh:

Year:  2016        PMID: 27600136     DOI: 10.1208/s12248-016-9972-4

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  38 in total

1.  Pharmacodynamic modeling of the acid inhibitory effect of ranitidine in patients in an intensive care unit during prolonged dosing: characterization of tolerance.

Authors:  R A Mathôt; W P Geus
Journal:  Clin Pharmacol Ther       Date:  1999-08       Impact factor: 6.875

2.  Concomitant use of gastric acid-reducing agents is frequent among HIV-1-infected patients receiving protease inhibitor-based highly active antiretroviral therapy.

Authors:  J van Lunzen; H Liess; K Arastéh; R Walli; B Daut; D Schürmann
Journal:  HIV Med       Date:  2007-05       Impact factor: 3.180

3.  Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole.

Authors:  T W Chin; M Loeb; I W Fong
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

4.  The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria.

Authors:  Marc R Yago; Adam Frymoyer; Leslie Z Benet; Gillian S Smelick; Lynda A Frassetto; Xiao Ding; Brian Dean; Laurent Salphati; Nageshwar Budha; Jin Y Jin; Mark J Dresser; Joseph A Ware
Journal:  AAPS J       Date:  2014-10-02       Impact factor: 4.009

5.  pH-dependent dissolution in vitro and absorption in vivo of weakly basic drugs: development of a canine model.

Authors:  Rong Zhou; Paul Moench; Christopher Heran; Xujin Lu; Neil Mathias; Teresa N Faria; Doris A Wall; Munir A Hussain; Ronald L Smith; Duxin Sun
Journal:  Pharm Res       Date:  2005-02       Impact factor: 4.200

6.  Effect of pH and comedication on gastrointestinal absorption of posaconazole: monitoring of intraluminal and plasma drug concentrations.

Authors:  Jeroen Walravens; Joachim Brouwers; Isabel Spriet; Jan Tack; Pieter Annaert; Patrick Augustijns
Journal:  Clin Pharmacokinet       Date:  2011-11-01       Impact factor: 6.447

Review 7.  Drug-drug interaction profiles of proton pump inhibitors.

Authors:  Ryuichi Ogawa; Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2010-08       Impact factor: 6.447

8.  Evaluation of Escherichia coli membrane preparations of canine CYP1A1, 2B11, 2C21, 2C41, 2D15, 3A12, and 3A26 with coexpressed canine cytochrome P450 reductase.

Authors:  Charles W Locuson; Brian T Ethell; Michael Voice; David Lee; Kenneth L Feenstra
Journal:  Drug Metab Dispos       Date:  2008-12-12       Impact factor: 3.922

9.  Effects of ranitidine and sucralfate on ketoconazole bioavailability.

Authors:  S C Piscitelli; T F Goss; J H Wilton; D T D'Andrea; H Goldstein; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

Review 10.  Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals.

Authors:  T T Kararli
Journal:  Biopharm Drug Dispos       Date:  1995-07       Impact factor: 1.627

View more
  5 in total

1.  Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations.

Authors:  Tanay S Samant; Shyeilla Dhuria; Yasong Lu; Marc Laisney; Shu Yang; Arnaud Grandeury; Martin Mueller-Zsigmondy; Kenichi Umehara; Felix Huth; Michelle Miller; Caroline Germa; Mohamed Elmeliegy
Journal:  Clin Pharmacol Ther       Date:  2017-12-08       Impact factor: 6.875

2.  pH-Dependent Molecular Gate Mesoporous Microparticles for Biological Control of Giardia intestinalis.

Authors:  Isabel González-Alvarez; Verónica Vivancos; Carmen Coll; Bárbara Sánchez-Dengra; Elena Aznar; Alejandro Ruiz-Picazo; Marival Bermejo; Félix Sancenón; María Auxiliadora Dea-Ayuela; Marta Gonzalez-Alvarez; Ramón Martínez-Máñez
Journal:  Pharmaceutics       Date:  2021-01-13       Impact factor: 6.321

3.  Non-Effective Improvement of Absorption for Some Nanoparticle Formulations Explained by Permeability under Non-Sink Conditions.

Authors:  Kazuya Sugita; Noriyuki Takata; Etsuo Yonemochi
Journal:  Pharmaceutics       Date:  2022-04-07       Impact factor: 6.525

4.  On the Usefulness of Two Small-Scale In Vitro Setups in the Evaluation of Luminal Precipitation of Lipophilic Weak Bases in Early Formulation Development.

Authors:  Patrick J O'Dwyer; Georgios Imanidis; Karl J Box; Christos Reppas
Journal:  Pharmaceutics       Date:  2020-03-16       Impact factor: 6.321

Review 5.  New Insights of Oral Colonic Drug Delivery Systems for Inflammatory Bowel Disease Therapy.

Authors:  Adrian H Teruel; Isabel Gonzalez-Alvarez; Marival Bermejo; Virginia Merino; Maria Dolores Marcos; Felix Sancenon; Marta Gonzalez-Alvarez; Ramon Martinez-Mañez
Journal:  Int J Mol Sci       Date:  2020-09-05       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.